Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) has announced the acquisition of a new facility in Zhangjiagang, China, marking a strategic expansion phase. This 32,000 square meter facility will support the production of pre-sterilized EZ-fill® syringes and vials, meeting the growing demand in the biotech sector. Construction is set to begin in spring 2022, with production expected to start in 2023 and operational lines by early 2024. The expansion aims to streamline the drug development supply chain, with the potential to double current production capabilities by the end of 2024.
Stevanato Group (NYSE: STVN) reported a 12.5% increase in fourth quarter revenue to €232.6 million, with diluted EPS at €0.17 and adjusted EPS at €0.13. Full year revenue rose by 27.5% to €843.9 million. The company announced guidance for 2022, expecting revenue between €935 million to €945 million, with adjusted EPS projected at €0.49 to €0.51. Key drivers include strong performance in high-value solutions and demand for Covid-related products. The backlog also increased to €880 million, indicating robust future growth.
Stevanato Group (NYSE: STVN) has secured approximately $95 million from the Biomedical Advanced Research and Development Authority (BARDA) to enhance vial production at its Fishers, Indiana facility. This funding aims to strengthen U.S. capabilities for addressing public health emergencies by expanding the company's manufacturing capacity for standard and EZ-Fill® vials. CEO Franco Moro emphasized that this investment will bolster the U.S. pharmaceutical supply chain and scaling operations in a critical market.
Stevanato Group (NYSE: STVN) announced it will release its financial results for Q4 and full year 2021 on March 8, 2022, at 6:30 a.m. ET. A conference call is scheduled for 8:30 a.m. ET on the same day, during which management will discuss the results and refer to a slide presentation available on their Investor Relations website. Participants can preregister or access the live call via provided links. An online archive of the call will be accessible after the live session until March 22, 2022.
Stevanato Group has appointed Riccardo Butta as President of the Americas, reinforcing its commitment to growth in the region. Butta brings over 30 years of management experience, including 20 years at Flex Ltd., where he oversaw the global commercial operations of Flex Health Solutions. This strategic move aims to enhance market penetration and customer proximity amid growing regional demand. CEO Franco Moro expressed confidence in Butta's capabilities to advance the company’s strategic priorities in this critical area.
Stevanato Group has extended its licensing agreement with Haselmeier for the Axis-D™ pen injector technology, broadening its offerings beyond diabetes to include obesity, cardiovascular disease, gastrointestinal disorders, pain management, and more. This strategic move enhances Stevanato's product portfolio and positions it to meet the increasing demand for drug delivery systems. The Alina® platform is designed for a variety of therapeutic regimens, ultimately benefiting patients and pharmaceutical companies during the drug development process.
Stevanato Group (NYSE: STVN) announced the construction of a new 6,750 square meter corporate headquarters in Piombino Dese, Italy, aimed at enhancing its production capabilities. The facility will feature production lines for EZ-fill® solutions and serve as a hub for R&D and office space, reflecting the company's ongoing commitment to meet global demand. Construction began in September 2021, with operational production expected by mid-2022. This expansion is part of the company's 2020-2023 Industrial Plan.
Stevanato Group (NYSE: STVN) reported a 37% revenue increase to €214.5 million in Q3 2021, alongside a net profit of €18.6 million and diluted EPS of €0.07. Adjusted net profit rose 39% to €26.4 million, with adjusted diluted EPS at €0.10. The backlog also grew to €834 million. A discretionary bonus of €6.7 million affected net profits, but the company remains optimistic, raising its revenue guidance for the year and projecting adjusted diluted EPS between €0.45 and €0.47.
Stevanato Group S.p.A. (NYSE: STVN) announced it will release its third quarter fiscal 2021 financial results on November 9, 2021, at 6:30 a.m. ET. A conference call will follow at 8:30 a.m. ET, where management will present a slide deck available on their Investor Relations website. The call can be accessed by dialing provided numbers for various countries or via an online broadcast. A replay will be available until November 23, 2021. Founded in 1949, Stevanato is a key provider of drug containment, delivery, and diagnostic solutions for the pharmaceutical industry.
Summary not available.